MX2024004421A - Arn terapeutico para el cancer de pulmon. - Google Patents
Arn terapeutico para el cancer de pulmon.Info
- Publication number
- MX2024004421A MX2024004421A MX2024004421A MX2024004421A MX2024004421A MX 2024004421 A MX2024004421 A MX 2024004421A MX 2024004421 A MX2024004421 A MX 2024004421A MX 2024004421 A MX2024004421 A MX 2024004421A MX 2024004421 A MX2024004421 A MX 2024004421A
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- lung
- disclosed
- nsclc
- rnas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/078022 WO2023061550A1 (en) | 2021-10-11 | 2021-10-11 | Therapeutic rna for lung cancer |
| EP2022050135 | 2022-01-05 | ||
| PCT/EP2022/078084 WO2023061931A1 (en) | 2021-10-11 | 2022-10-10 | Therapeutic rna for lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004421A true MX2024004421A (es) | 2024-05-06 |
Family
ID=84286153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004421A MX2024004421A (es) | 2021-10-11 | 2022-10-10 | Arn terapeutico para el cancer de pulmon. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240415946A1 (https=) |
| EP (1) | EP4415747A1 (https=) |
| JP (1) | JP2024537298A (https=) |
| KR (1) | KR20240099175A (https=) |
| AR (1) | AR127317A1 (https=) |
| AU (1) | AU2022365280A1 (https=) |
| CA (1) | CA3234915A1 (https=) |
| IL (1) | IL312026A (https=) |
| MX (1) | MX2024004421A (https=) |
| TW (1) | TW202333803A (https=) |
| WO (1) | WO2023061931A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025201659A1 (en) * | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001231204A1 (en) * | 2000-01-27 | 2001-08-07 | Sidney Kimmel Cancer Center | Genetically engineered tumor cell vaccines |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| US20180126003A1 (en) * | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| TW202134430A (zh) * | 2019-12-03 | 2021-09-16 | 美商紐沃進公司 | 腫瘤細胞疫苗 |
-
2022
- 2022-10-07 TW TW111138246A patent/TW202333803A/zh unknown
- 2022-10-10 EP EP22802066.5A patent/EP4415747A1/en active Pending
- 2022-10-10 CA CA3234915A patent/CA3234915A1/en active Pending
- 2022-10-10 IL IL312026A patent/IL312026A/en unknown
- 2022-10-10 WO PCT/EP2022/078084 patent/WO2023061931A1/en not_active Ceased
- 2022-10-10 MX MX2024004421A patent/MX2024004421A/es unknown
- 2022-10-10 AU AU2022365280A patent/AU2022365280A1/en active Pending
- 2022-10-10 US US18/699,937 patent/US20240415946A1/en active Pending
- 2022-10-10 JP JP2024521854A patent/JP2024537298A/ja active Pending
- 2022-10-10 KR KR1020247012038A patent/KR20240099175A/ko active Pending
- 2022-10-11 AR ARP220102747A patent/AR127317A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR127317A1 (es) | 2024-01-10 |
| WO2023061931A1 (en) | 2023-04-20 |
| IL312026A (en) | 2024-06-01 |
| US20240415946A1 (en) | 2024-12-19 |
| JP2024537298A (ja) | 2024-10-10 |
| TW202333803A (zh) | 2023-09-01 |
| EP4415747A1 (en) | 2024-08-21 |
| AU2022365280A1 (en) | 2024-05-02 |
| KR20240099175A (ko) | 2024-06-28 |
| CA3234915A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| AR124438A1 (es) | Rna terapéutico para tratar el cáncer | |
| CL2022002808A1 (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas | |
| CL2025001937A1 (es) | Arn terapéutico para el cáncer positivo para vph | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2024004418A (es) | Arn terapéutico para cáncer de pulmón. | |
| MX390121B (es) | Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas. | |
| WO2007071409A8 (en) | Method for treating colon cancer | |
| Zheng et al. | Graphene-based materials: A new tool to fight against breast cancer | |
| NZ726365A (en) | Combinations for treating cancers | |
| MX2024004421A (es) | Arn terapeutico para el cancer de pulmon. | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| Sun et al. | Hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer: 5-year follow-up result of a randomized trial | |
| CO2023016058A2 (es) | Agentes de rnai para inhibir la expresión de mucina 5ac (muc5ac), composiciones de estos y métodos de uso | |
| JOP20200124A1 (ar) | طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك | |
| MX2024003563A (es) | Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa. | |
| MX2021001764A (es) | Terapia de combinacion. | |
| CO2023012853A2 (es) | Exosomas cargados con el factor 1 asociado a fas (faf1) y su uso como agente anticáncer | |
| Yu et al. | “Pacific” modality in locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis of a real-world multicenter study | |
| Chen et al. | Application and progress of photodynamic therapy in combination therapy of lung cancer | |
| CL2023000037A1 (es) | Arn terapéutico para el cáncer positivo para vph | |
| Rasskazova et al. | Organ-sparing treatment for breast cancer | |
| Accioly et al. | Effect of umbilical cord mesenchymal stem cells secretome in melanoma | |
| Vagashiya et al. | Recurrence Developing 21 Years after Treatment of Breast Cancer |